Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 8, 2000, Pages 2309-2317

  Murata, Toshinori ^b,c   He, Shikun ^a   Hangai, Masanori ^b   Ishibashi, Tatsuro ^c   Xi, Xiao Ping ^d   Kim, Sarah ^d   Hsueh, Willa A ^d   Ryan, Stephen J ^a,b   Law, Ronald E ^d   Hinton, David R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DOHENY EYE INSTITUTE   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA STIMULATING AGENT; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATTLE; CELL MIGRATION; CELL PROLIFERATION; CHOROID; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; FETUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LASER COAGULATION; MALE; MONKEY; NONHUMAN; PIGMENT CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; BLOTTING, WESTERN; CELL DIVISION; CELL MOVEMENT; CHOROID; CHOROIDAL NEOVASCULARIZATION; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; LASER COAGULATION; LIGANDS; LYMPHOKINES; MACACA FASCICULARIS; MALE; PIGMENT EPITHELIUM OF EYE; RATS; RATS, INBRED BN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 2142701648     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bressler NM, Bressler SB. Preventative ophthalmology: age-related macular degeneration. Ophthalmology. 1995;102:1296-1211.
2. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
3. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol. 1998;43: 134-146.
4. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated RPE cells and VEGF immunoreactivity in surgically-excised ARMD-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
5. Shen WY, Yu MJT, Barry CJ, Constable IJ, Rakoczy PE. Expression of cell adhesion and vascular endothelial growth factor in experimental choroidal neovascularization in the rat. Br J Ophthalmol. 1996;82:1063-1071.
6. Wells JA, Murphy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization. Br J Ophthalmol. 1996;80:363-366
7. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37: 1929-1934.
8. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162
9. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
10. Kubota T, Koshizuki K, Williamson EA, Asou H, Said JW, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer in vitro and in vivo Cancer Res. 1998;58:3344-3352.
11. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am. 1997;26:553-573.
12. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab. 1999;84:1165-1171.
13. Lehman JM, Morre LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem. 1995;270:12953-12956.
14. Wiesenberg I, Chiesi M, Missbach C, et al. Specific activation of the nuclear receptors PPARγ and RXRα by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Mol Pharmacol. 1998;53:1131-1138.
15. Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998;284:751-759.
16. Tontonoz P, Hu E, Graves RA, Budavari AB, Spiegelman BM. MP-PAR-gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1996;8:1224-1208.
17. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 1996;137:354-366.
18. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46:1319-1327.
19. Iijima K, Yoshizumi M, Ako J, et al. Expression of peroxisome proliferator-activated receptor-γ (PPARγ) in rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1998;247:353-356.
20. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
21. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
22. Marx N, Sukhova G, Murphy C, Libby P, Plutzky. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisome proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17-23.
23. Law RE, Meehan WP, Xi X-P, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest. 1996;98:1897-1905.
24. Park KS, Ciaraldi TP, Lindgren K, et al. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 1998;83:2830-2835.
25. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer in vitro and in vivo. Cancer Res. 1998;58:3344-3352.
26. Min/+ mice. Nat Med. 1998;4:1053-1057.
27. Demetri GD, Fletcher CDM, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc Natl Acad Sci USA. 1999;96:3951-3956.
28. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998;4:1046-1052.
29. Xin X, Yang S, Kowalski J, Gervitsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;13:9116-9119.
30. Bourcier MN, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546-551.
31. Gralinski MR, Rowse PE, Breider MA. Effects of troglitazonc and pioglitazone on cytokine-mediated endothtlial cell proliferation in vitro. J Cardiovasc Pharmacol. 1998;31:909-913.
32. Satoh H, Tsukamoto K, Hashimoto Y, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR-gamma on vascular endothelial function. Biochem Biophys Res Commun. 1999;254:757-763.
33. Parenti A, Morbidelli L, Cui XL, et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium. J Biol Chem; 1997;273:4220-4226.
34. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272:32521-32527.
35. Eliceiri BP, Klemke R, Stromblad S, Cherish DA. Integrin alphav-beta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998;140:1255-1263.
36. Graf K, Xi XP, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett. 1998;400:119-121.
37. Ryan SJ. The development of an experimental model of subretinal neovascularization in disciform macular degeneration. Trans Am Ophthalmol Soc. 1979;77:707-745.
38. Dobi ET, Puliafito CA, Destro M. A new model of subretinal neovascularization in the rat. Arch Ophthalmol. 1989;107:267-269.
39. Shen WY, Yu MJT, Barry CJ, Constable IJ, Rakoczy PE. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularization in the rat. Br J Ophthalmol. 1998;82:1063-1071.
40. Miller H, Miller B, Ryan SJ. Newly-formed subretinal vessels: fine structure and fluorescein leakage. Invest Ophthalmol Vis Sci. 1986;27:204-213.
41. Schubert CA, Kimura H, Spee C, et al. Retrovirus-mediated transfer of the suicide gene into retinal pigment epithelial cells in vitro. Curr Eye Res. 1997;16:656-662.
42. Hoffmann S, Spec C, Murata T, et al. Rapid isolation of choriocapillary endothelial cells by Lycopersicon esculentum-coated dynabeads. Graefes Arch Clin Exp Ophthalmol. 1998;236:779-784.
43. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-1489.
44. Takehana Y, Kurokawa T, Kitamura T, et al. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest Ophthalmol Vis Sci. 1999;40:459-466.
45. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol. 1995;164:385-394.
46. Yanase T, Yashiro T, Takitani K, et al. Differential expression of PPARγ1 and γ2 isoforms in human adipose tissue. Biochem Biophys Res Commun. 1997;233:320-324.
47. Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997;235:113-116.
48. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
49. Law RE, Goetze S, Xi X-P, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
50. Sakamoto T, Hinton DR, Kimura H, et al. Vitamin E succinate inhibits proliferation and migration of retinal pigment epithelial cells in vitro: therapeutic implication for proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1996;234:186-192.